Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;109(7):2271-2276.
doi: 10.3324/haematol.2023.283610.

Pubertal development of transfusion-dependent thalassemia patients in the era of oral chelation with deferasirox: results from the French registry

Mathilde Veneziano Broccia  1 , Julia Vergier  2 , Audrey Benoit  3 , Yoann Huguenin  4 , Anne Lambilliotte  5 , Marie Pierre Castex  6 , Stephanie Gourdon  7 , Ghislaine Ithier  8 , Kamila Kebaili  9 , Pierre Rohrlich  10 , Corinne Pondarre  11 , Abdourahim Chamouine  12 , Pauline Simon  13 , Kokou Placide Agbo Kpati  14 , Slimane Allali  15 , Sandrine Baron-Joly  16 , Sophie Bayart  17 , Nicolas Billaud  18 , Valentine Brousse  19 , Cecile Dumesnil  20 , Nathalie Garnier  9 , Isabelle Guichard  21 , Laure Joseph  22 , Annie Kamdem  23 , Julie Maitre  24 , Catherine Mathey  25 , Catherine Paillard  26 , Aurelie Phulpin  27 , Cecile Renard  9 , Cecile Stoven  28 , Mohamed Touati  29 , Capucine Trochu  30 , Suzanne Mathieu Nafissi  31 , Catherine Badens  3 , Sarah Szepetowski  32 , Isabelle Thuret  32
Affiliations

Pubertal development of transfusion-dependent thalassemia patients in the era of oral chelation with deferasirox: results from the French registry

Mathilde Veneziano Broccia et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study population. DFX: deferasirox; HSCT: hematopoietic stem cell transplantation; TDT: transfusion-dependent thalassemia.
See this image and copyright information in PMC

References

    1. Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and b-thalassemia: a systematic review. Am J Hematol. 2018;93(7):943-952. - PubMed
    1. Forni GL, Gianesin B, Musallam KM, et al. . Overall and complication-free survival in a large cohort of patients with b-thalassemia major followed over 50 years. Am J Hematol. 2023;98(3):381-387. - PubMed
    1. De Sanctis V, Eleftheriou A, Malaventura C; Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2 Suppl:2249-255. - PubMed
    1. Thuret I, Pondarré C, Loundou A, et al. . Complications and treatment of patients with b-thalassemia in France: results of the National Registry. Haematologica. 2010;95(5):724-729. - PMC - PubMed
    1. Soliman AT, Yassin MA, De Sanctis V. Final adult height and endocrine complications in young adults with b-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC. Acta Biomed. 2018;89(2-S):27-32. - PMC - PubMed

Publication types